Citalopram Hydrobromide

Phase 3Small molecule

TTorrent Pharmaceuticals Limited

Citalopram Hydrobromide is one of 129 small molecule programs targeting Anxiety. It is currently in Phase 3.

Indications

Total Trials

Active Trials

128

Competitors

Pipeline

Status by Indication[3][1]

Indication

AnxietyActive, not recruiting

Breast CancerActive, not recruiting

Hot FlashesActive, not recruiting

AutismActive, not recruiting

AnxietyPreclinical

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

Hot FlashesPhase 3

Active, not recruiting

AutismPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Citalopram Hydrobromide

TTorrent Pharmaceuticals Limited

Phase 3

1 2

Tykerb

GSK

Preclinical

80 3

Trodelvy

Gilead

Preclinical

37 4

Adriamycin

GGynecologic Oncology Group

Preclinical

87 5

Avastin

Prolia

14 7

Gemzar

GGynecologic Oncology Group

Preclinical

22 8

Megace

Bristol-Myers Squibb

Preclinical

4 9

Voltaren

Novartis

Preclinical

1 10

Lupron

EEastern Cooperative Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

MACE2 trials

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects Under Fasting Condition

Completed·TTorrent Pharmaceuticals Limited·Phase 1·NCT00940238

Completed·TTorrent Pharmaceuticals Limited·Phase 1·NCT00939835

Fasting Conditions1 trial

Bioequivalence Study of Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions

Completed·—·Phase 1·NCT01149967·24 enrolled

Anxiety1 trial

Efficacy and Feasibility of a Personalized Treatment for Depression With Co-Occurring Anxiety

Completed·UUniversity of Pittsburgh·N/A·NCT00930293·50 enrolled

Autism1 trial

Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)

Completed·—·Phase 2·NCT00086645·149 enrolled

Breast Cancer1 trial

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

Completed·MMayo Clinic··NCT00667121·88 enrolled

2 more indications

Labor1 trial

Bioequivalence Study of Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions

Completed·—·Phase 1·NCT01149980·24 enrolled

Hot flashes1 trial

Citalopram in Treating Postmenopausal Women With Hot Flashes

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00363909·254 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Citalopram Hydrobromide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Citalopram Hydrobromide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Citalopram Hydrobromide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Torrent Pharmaceuticals Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTorrent Pharmaceuticals Limited

Citalopram Hydrobromide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

MACE2 trials

Fasting Conditions1 trial

Anxiety1 trial

Autism1 trial

Breast Cancer1 trial

Labor1 trial

Hot flashes1 trial

References

Drug Info

Quick Facts

Related News